These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. Potkin SG; Cohen M; Panagides J J Clin Psychiatry; 2007 Oct; 68(10):1492-500. PubMed ID: 17960962 [TBL] [Abstract][Full Text] [Related]
26. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
27. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
28. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749 [TBL] [Abstract][Full Text] [Related]
29. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. Kemp DE; Johnson E; Wang WV; Tohen M; Calabrese JR J Clin Psychiatry; 2011 Sep; 72(9):1236-41. PubMed ID: 21457677 [TBL] [Abstract][Full Text] [Related]
30. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. Bozzatello P; Rocca P; Uscinska M; Bellino S CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044 [TBL] [Abstract][Full Text] [Related]
32. Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. Tang Y; Wu Y; Li X; Hao Q; Deng W; Yue W; Yan H; Zhang Y; Tan L; Chen Q; Yang G; Lu T; Wang L; Yang F; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Li L; Wang C; Ma X; Zhang D; Yu H; Zhao L; Ren H; Wang Y; Zhang G; Li C; Du X; Hu X; Li T; Wang Q Curr Neuropharmacol; 2023; 21(2):424-436. PubMed ID: 36411567 [TBL] [Abstract][Full Text] [Related]
33. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. Kemp DE; Ganocy SJ; Brecher M; Carlson BX; Edwards S; Eudicone JM; Evoniuk G; Jansen W; Leon AC; Minkwitz M; Pikalov A; Stassen HH; Szegedi A; Tohen M; Van Willigenburg AP; Calabrese JR J Affect Disord; 2011 Apr; 130(1-2):171-9. PubMed ID: 21071096 [TBL] [Abstract][Full Text] [Related]
34. New generation antipsychotics for first episode schizophrenia. Rummel C; Hamann J; Kissling W; Leucht S Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012 [TBL] [Abstract][Full Text] [Related]
35. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. Harvey RC; James AC; Shields GE CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655 [TBL] [Abstract][Full Text] [Related]
36. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
37. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. Ogyu K; Noda Y; Yoshida K; Kurose S; Masuda F; Mimura Y; Nishida H; Plitman E; Tarumi R; Tsugawa S; Wada M; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S Neuropsychopharmacol Rep; 2020 Jun; 40(2):138-149. PubMed ID: 32180369 [TBL] [Abstract][Full Text] [Related]
38. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Liu-Seifert H; Osuntokun OO; Feldman PD Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400 [TBL] [Abstract][Full Text] [Related]
39. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia. Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500 [TBL] [Abstract][Full Text] [Related]
40. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]